6d), while the risk of death with late-life L2-Cmu treatment was 62.2% (40.7%, 95.2%) of that observed for controls ( P = 0.029)
still has a different regulatory history than CJC-1295
Although our study was designed in accordance with regulatory guidelines, we acknowledge that the observed variability may have limited the precision of our estimates
Chapters: 00:00 Intro & Podcast Catch-Up 11:13 Peptide Testing & Quality Concerns 20:16 IGF-1, HGH & Stack Overlap 29:20 Womens Hormones & Hysterectomy 32:15 Menopause, Weight Gain & Peptides 44:16 Peptide Storage & Shelf Life 49:44 NAD+ Crystallization Explained 51:37 Growth Hormones for Women (Age 44) 59:44 Low Testosterone & Mental Health (Age 28) 1:05:48 Building Muscle Without Steroids (Athlete Q&A) We cover: Why Peptide Companies Don't Test for Endotoxins & Heavy Metals: The real cost breakdown, why cheap peptides come with trade-offs, and how quality standards are rising Kisspeptin on TRT Why It Won't Work: How TRT shuts down the signal kisspeptin needs and why HCG is the smarter choice for testicular health on cycle IGF-1 LR3 Stacking Rules: Why combining HGH, secretagogues, and IGF-1 all at once is too much on the same pathway and how to rotate smarter Peptide Shelf Life & Storage Explained: Bacteriostatic vs
It exhibits greater androgen receptor activity in skeletal muscle cells than in prostate cells, with tissue-specific effects driven by differential co-factor recruitment rather than tissue concentration
